Recently, new oral cephalosporins, which are esterified with the pivaloyloxymethyl group to improve intestinal absorption, have been developed in Japan. It has been reported that several pivaloyloxymethyl ester derivatives, such as cefteram pivoxil, reduce the amount of carnitine in the body (6, 15) . Therefore, it is necessary to administer these drugs with caution to patients with carnitine deficiency (14) . A better approach is the development of new oral cephalosporins that are well absorbed without esterification of the pivaloyloxymethyl group, in addition to having broad and potent antibacterial activities. S-1090, (Ϫ)-(6R,7R)-7-[(Z)-2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido]-8-oxo-3-(1H-1,2,3-triazol-4-yl) thiomethylthio-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrochloride monohydrate, is a new synthetic, nonesterified, oral cephalosporin that has been developed to overcome this problem ( Fig. 1) . In the present study, we compared the in vitro and in vivo potencies of S-1090 with those of cefdinir (11) , cefpodoxime (16) , cefaclor, cefditoren (8) , saropenem (12) , amoxicillin, and ofloxacin.
The following antimicrobial agents were obtained from the indicated sources: S-1090 and cefaclor, Shionogi & Co. (Osaka, Japan); cefdinir and amoxicillin, Fujisawa Pharmaceutical Co. (Osaka, Japan); cefpodoxime and cefpodoxime proxetil, Sankyo Co. (Tokyo, Japan); cefditoren and cefditoren pivoxil, Meiji Seika Kaisha (Tokyo, Japan); saropenem, Suntory Co. (Osaka, Japan); and ofloxacin, Daiichi Pharmaceutical Co., (Tokyo, Japan). Since S-1090 is adsorbed by glass or plastic, the antibiotic solution was prepared in a silicone-coated tube (Becton Dickinson & Co., Rutherford, N.J.).
Most bacterial strains used in the present study were clinical isolates collected at Toho University Hospital and were stored at Ϫ80ЊC.
The MICs were determined by the broth microdilution method as described in the guidelines of the Japanese Society for Chemotherapy (1, 2) . We used cation-adjusted MuellerHinton broth (Difco, Detroit, Mich.) with appropriate concentrations of the divalent cations Ca 2ϩ and Mg 2ϩ for nonfastidious aerobic bacteria. The broth was supplemented with 5% lysed horse blood for Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, Enterococcus faecalis, Enterococcus faecium, and Moraxella catarrhalis. We also used cation-adjusted Mueller-Hinton broth supplemented with 5% lysed horse blood, 5 mg of yeast extract (Oxoid, Basingstoke, England) per ml, and 15 g of NAD (Sigma Chemical Co., St. Louis, Mo.) per ml for Haemophilus influenzae. The bactericidal activities of S-1090 and the other agents at four times the MIC for Escherichia coli ATCC 25922 were determined. An overnight culture in Mueller-Hinton broth was inoculated into fresh broth, and the mixture was incubated, with constant shaking, until the viability reached 2 ϫ 10 6 to 3 ϫ 10 6 CFU/ml. After the addition of antibiotics, the cultures were incubated at 35ЊC and the number of viable cells was determined.
The potency of S-1090 was determined in a mouse model of bacteremia. Male SLC/ICR mice weighing 18 to 22 g (Sankyo Labo Service Co., Tokyo, Japan) were injected intraperitoneally with a portion of a 0.5-ml dose of a bacterial suspension (approximately 100 times the 50% lethal dose) in either saline or 5% mucin (Difco). S-1090 and the other antibiotics were formulated with 0.5% methylcellulose (Wako Pure Chemical Industries, Osaka, Japan) and were administered orally 1 h after the induction of infection. Mortality was recorded over 7 days to estimate the 50% effective dose (ED 50 ), which was determined by probit analysis (7) .
The efficacy of S-1090 against respiratory infection was determined by using a mouse model of intranasal infection with S. pneumoniae TUH 39. Under pentobarbital anesthesia (50 mg/kg of body weight), 4-week-old female SLC/ICR mice (body weight, 18 to 22 g; n ϭ 10) were infected by instillation of a bacterial suspension. Drugs were administered orally at 12 h after infection twice daily every 12 h for a period of 3 days.
The therapeutic effects of S-1090 and the other agents were tested in a mouse model of ascending urinary tract infection induced by E. coli TMS 3 by the method described by Oomori et al. (13) . Four-week-old female SLC/ICR mice (weight, 16 to 20 g) were used. Dietary intake was restricted to water for 20 h prior to infection. Under ether anesthesia, a polyethylene catheter (Marukyu, Tokyo, Japan) was introduced transurethrally to inject 0.05 ml of bacterial suspension into the bladder. The urethral catheter was removed immediately after inoculation, and the external urethral meatus was clamped for 1 h. Drugs were administered orally 24 h after infection at dosages ranging from 0.2 to 20 mg/kg twice daily every 12 h for a period of 3 days. Mice were sacrificed 2 days after administra-tion of the last dose of the test drug, and the number of viable cells in the kidneys was determined.
We examined the in vitro antibacterial activity of S-1090 against 938 recent clinical isolates of gram-positive and gramnegative aerobic bacteria. The MICs at which 50 and 90% of isolates are inhibited (MIC 50 s and MIC 90 s, respectively) as well as the MIC range of each drug for the bacteria tested are listed in Table 1 . S-1090 was potent against methicillin-susceptible Staphylococcus aureus isolates. However, it was less active than saropenem, had activity similar to that of cefdinir, but was more active than the other agents against which it was compared. S-1090 was also active against methicillin-susceptible Staphylococcus epidermidis (MIC 90 , 0.25 g/ml). S-1090 (MIC 90 , 0.125 g/ml) had the same potent activity as cefdinir and saropenem against Staphylococcus warneri, but it was more active than the other agents tested. S-1090 was the most active compound among the compounds tested against S. pyogenes and S. agalactiae. The activity of S-1090 against S. pneumoniae was similar to that of cefdinir, but it was twofold more active than cefpodoxime and ofloxacin and was less active than cefditoren, saropenem, and amoxicillin. The potency of S-1090 against gram-negative bacteria was comparable to that of cefdinir but was higher than that of cefdinir against Morganella morganii, Citrobacter freundii, Bordetella pertussis, Helicobacter pylori, and H. influenzae. S-1090 was the most active compound against Neisseria gonorrhoeae.
S-1090 showed bactericidal activity against E. coli ATCC 25922 at four times the MIC (Fig. 2) . Its bactericidal activity exceeded those of cefdinir, cefpodoxime, and cefaclor.
The in vivo efficacy of S-1090 was compared with those of cefdinir, cefpodoxime proxetil, cefditoren pivoxil, cefaclor, and ofloxacin against experimentally induced acute bacteremia in mice ( Table 2) . S-1090 against S. aureus Smith (ED 50 , 2.13 mg/kg) was less efficacious than cefaclor, but S-1090 was more effective than cefdinir and ofloxacin. The ED 50 s of cefpodoxime proxetil and cefditoren pivoxil were both greater than 15 mg/kg against S. aureus Smith. S-1090 was the most effective compound against S. pneumoniae TUH 39. Against gram-negative pathogens of E. coli C-11 and Klebsiella pneumoniae 3K-25, the ED 50 s of S-1090 were less than 5 mg/kg.
Against respiratory tract infections induced by inoculation of S. pneumoniae TUH 39, S-1090 was less effective than amoxicillin but was as effective as cefpodoxime proxetil and was more effective than cefdinir (Table 2) . Against ascending urinary tract infections induced by inoculation of E. coli TMS 3 in mice, the antibacterial activity of S-1090 in mice treated with the drug at 2 or 20 mg/kg per dose was significantly different from that in the control group of mice (P Ͻ 0.05) but not that in mice treated with the other agents tested (Table 3) . Treatment with S-1090 resulted in a greater reduction in the number of organisms compared with that after treatment with cefdinir, cefpodoxime proxetil, and cefaclor.
Oral cephalosporins have been used to treat mild forms of infection, such as dermal and soft tissue infections, urinary tract infections, bronchitis, and otitis media. The main causative organisms in these infections are S. aureus, Staphylococcus epidermidis, S. pneumoniae, E. coli, H. influenzae, and K. pneumoniae. In addition, the clinical significance of other coagulase-negative staphylococci had steadily increased (5). Until recently, these organisms were regarded by clinicians and microbiologists as contaminants present in clinical specimens. Therefore, it is important that orally administered drugs have antibacterial activity against these gram-positive pathogens. In the present study, S-1090 was the most active compound against S. pyogenes and S. agalactiae and was as active as cefdinir against staphylococci. It was more active than cefdinir against E. faecalis. Cefixime, which contains the carboxymethoxyimino aminothiazole side chain at the 7 position, has been demonstrated to be potent against gram-negative pathogens but less active against gram-positive pathogens (3). By introducing the hydroxyimino group instead of the carboxymethoxyimino group in the side chain at position 7, cefdinir became more active than cefixime against gram-positive pathogens (11) . While S-1090 has the same side chain as cefdinir at the 7 position, it contains a new triazolthiomethylthio group in the side chain at the 3 position. This side chain has a chemical structure different from that of cefdinir. The chemical structure suggests that new side chain at position 3 enhances the activity of S-1090 against gram-positive organisms. Thus, S-1090 represents an advance in the activities of oral expanded-spectrum cephalosporins against gram-positive and -negative pathogens. This new drug also showed strong bactericidal activity against E. coli ATCC 25922; against this strain, the activity of S-1090 was greater than those of cefdinir, cefpodoxime, and cefaclor.
Our results demonstrated that S-1090 is more effective than cefdinir against S. aureus Smith and S. pneumoniae TUH 39 in systemic infections. Furthermore, S-1090 showed a therapeutic effect against localized infections such as those in the ascending urinary and respiratory tracts. Overall, the in vivo efficacy of S-1090 was better than expected from its in vitro activities and was better than the in vitro and in vivo activities of the other agents tested. One speculation for the reasons for these results is that S-1090 produced higher levels in plasma and a longer half-life in plasma compared with those of the nonester oral cephalosporins in various experimental animals (4) and humans (9) . The results of the present study in mice, together with those of pharmacokinetic studies in humans, suggest that /ml) ; å, cefdinir at four times the MIC (1 g/ml); Ç, cefpodoxime at four times the MIC (2 g/ml); s, cefaclor at four times the MIC (8 g/ml).
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NOTES 2545 a CNS, coagulase-negative staphylococci, including Staphylococcus saprophyticus (n ϭ 5), Staphylococcus lugdunensis (n ϭ 3), Staphylococcus simulans (n ϭ 3), Staphylococcus hominis (n ϭ 2), Staphylococcus schleiferi (n ϭ 2), Staphylococcus captis (n ϭ 1), and Staphylococcus felis (n ϭ 1).
b GC agar (Difco) supplemented with 2% hemoglobin and 1% defined supplement (10) was used to test Neisseria gonorrhoeae isolates, which were incubated in 5% CO 2 at 35ЊC for 24 h.
c The MICs were determined by the agar dilution method with an inoculum of 10 4 CFU per spot (10) . d Blood agar base no. 2 (Oxoid) was used; it was supplemented with 7% horse blood, and the mixture was incubated under the CampyPak system (BBL, Cockeysville, Md.) at 35ЊC for 48 h.
e Bordet Gengou agar (Difco) supplemented with 15% horse blood and 1% glycerol was used, and the mixture was incubated at 35ЊC for 48 h.
S-1090 is a promising oral cephalosporin for the treatment of infections caused by a variety of gram-positive and gram-negative bacteria. 
